Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Crucell  /  Maanddraad December

Crucell« Terug naar discussie overzicht

Maanddraad December

Volgen
278 Posts
Pagina: 1 2 3 4 5 6 ... 14 »» | Laatste | Omlaag ↓
  3. MeawandMoo1 3 december 2008 02:20
    www.gavialliance.org/media_centre/pre...
    ......
    Responding to increased demand by poor countries to immunise children under five, the GAVI Alliance has committed to fund an additional US$ 134 million in new and continued programmes yesterday for vaccines against rotavirus, pneumococcal disease and Haemophilus influenzae type b (Hib).

    The programmes will support 11 countries and provide vaccines to an estimated 6.6 million children.
    .......
    Armenia, Bhutan, Cambodia, Laos, and Sao Tome will receive support to immunise approximately 2.9 million children with the life-saving Hib vaccine. It will be administered through three shots of a pentavalent vaccine that also includes antigens against diphtheria, tetanus, pertussis, and hepatitis B.
    .......
    Drie doses? helaas geen Quivaxem, neem ik aan.

    Since GAVI was launched in 2000, the number of poor countries that have accessed the Alliance’s life-saving support has skyrocketed. Requests from countries for hepatitis B vaccine, for example, have risen from nearly zero to more than 60 countries in just eight years.
  6. [verwijderd] 3 december 2008 09:27
    quote:

    MeawandMoo1 schreef:

    .......
    Armenia, Bhutan, Cambodia, Laos, and Sao Tome will receive support to immunise approximately 2.9 million children with the life-saving Hib vaccine. It will be administered through three shots of a pentavalent vaccine that also includes antigens against diphtheria, tetanus, pertussis, and hepatitis B.
    .......
    Drie doses? helaas geen Quivaxem, neem ik aan.

    Is QV: drie injecties met een pentavalent. QV is fully liquid penta.
  7. [verwijderd] 3 december 2008 09:48
    quote:

    eddy59 schreef:

    Crucell and Novavax Announce PER.C6(TM)
    Er stond vanochtend in de telegraaf dat DSM volgend jaar het middel gaat voordragen aan de FDA.
    Weet iemand hier meer over?
    Bedoel je dit eddy?

    di 02 dec 2008, 08:05 DSM levert bestanddeel artrosemedicijn

    HEERLEN (AFN) - Chemieconcern DSM gaat een belangrijk bestanddeel produceren van een medicijn tegen artrose waar de Franse biofarmaceut Nicox aan werkt. Daartoe hebben de twee een overeenkomst getekend. Dat heeft Nicox dinsdag bekendgemaakt.

    Naar verwachting levert DSM het middel op grote schaal vanaf het vierde kwartaal volgend jaar. Nicox heeft het medicijn recent met succes getest op artrosepatiënten. Het bedrijf verwacht medio volgend jaar een aanvraag in te dienen bij de Amerikaanse toezichthouder Food and Drug Administration voor goedkeuring van het medicijn.

    Dirk
  11. aossa 3 december 2008 14:12
    NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance

    NicOx S.A. (NYSE Euronext Paris: COX) today announced it has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod drug substance (or API, active pharmaceutical ingredient). Naproxcinod is NicOx' lead investigational product and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which recently achieved positive results in the third pivotal phase 3 study in osteoarthritis patients.

    Under the terms of the agreement, DSM will supply naproxcinod API for commercial purposes from its fine chemicals production site in Linz, Austria. DSM is one of the world's leading independent suppliers to the pharmaceutical industry, with some 40% of today's top-selling medicines in the world containing ingredients developed and produced by DSM. This follows the signature of an agreement with Capsugel in September 2008 for the commercial manufacture of naproxcinod oral capsules, which is widely recognized as the world leader in capsule manufacturing.

    Staffan Stromberg, Vice President of Technical Development and Operations at NicOx, commented: "The latest positive results observed in the 111 and 303 studies support our confidence in naproxcinod's blockbuster potential. We are therefore very pleased to have signed these contracts with global leaders in high capacity API and capsule production. We project these agreements should cover the high sales forecasts for the initial years of naproxcinod's commercialization that have been suggested by our market research."

    The agreement with DSM aims to secure commercial supplies of an appropriate scale to support the successful launch of naproxcinod. As per the agreement, NicOx envisages the first deliveries of significant quantities of commercial material being made from the fourth quarter of 2009 onwards. Following this agreement with DSM and the importance of cost control in the current economic environment, NicOx has ended its present API supply agreement with Archimica. At the point of termination, Archimica had met all contract milestones and was in full compliance with the other terms of the contract.

    Luca Mantovani, President & Business Unit Director at DSM Pharma Chemicals, declared: "We are happy to consolidate our relationship with NicOx through this agreement. Naproxcinod is an exciting compound and being part of its pre-launch and future commercialization plans is an interesting opportunity for DSM."

    On November 24, NicOx announced that the third pivotal phase 3 study for naproxcinod in osteoarthritis of the hip had met all three co-primary efficacy endpoints. Following the positive results from the 301 and 302 studies in osteoarthritis of the knee, 303 represents the third pivotal phase 3 study for naproxcinod to achieve p<0.001 on all three co-primary efficacy endpoints. In addition, naproxcinod 750 mg bid showed the same gastrointestinal (GI) adverse event rate and a similar blood pressure profile to placebo in the 303 study.

    This followed the announcement of positive results from a 118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111 study) on November 4, where naproxcinod showed a statistically significant reduction in systolic blood pressure of 3.8 mmHg (p=0.011) compared to naproxen over the whole study period. The filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

    DSM - the Life Sciences and Materials Sciences Company

    Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on the NYSE Euronext Amsterdam. More information: www.dsm.com.

    NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

    Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs and symptoms of osteoarthritis. Naproxcinod has completed three pivotal phase 3 studies with positive results and the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) is projected for mid-2009.

    Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

    NicOx S.A. is headquartered in France and is listed on the NYSE Euronext Paris (Compartment B: Mid Caps).

    This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

    For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).

    SOURCE NicOx
    www.fiercebiotech.com/node/42628/print
  13. Mr Greenspan 3 december 2008 14:32
    quote:

    aad100 schreef:

    en weinig aanbod. Geen last van shorters. Heb de indruk dat die al een tijdje niet meer opereren.
    Shorters zien meer brood in aandelen van ondernemingen waar paniek of onzekerheid kan ontstaan, zoals banken of ondernemingen die schulden moeten herfinancieren. Crucell is financieel gezond en heeft ipc fundamenteel een aardige bodem. Dat valt lang niet voor elk aandeel te zeggen. Zonder de overname van Berna was Crucell zeker doelwit van shorters geweest in deze tijden.
  14. [verwijderd] 5 december 2008 09:06
    Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by restructuring. Some even have to suspend operations or file for bankruptcy.

    Er zijn kansen. Ontwikkelaars kopen (kosten drukken), STAR/PerC6 inbrengen, weer verkopen.
  18. eddy59 5 december 2008 16:09
    quote:

    Nx4nX schreef:

    Alle calls gaan scherp omlaag. En puts ook. Huh??
    Inderdaad, echt vreemd mijn calls dec09 €12,00 stonden bij een koers van € 9,00 op € 2,00 en nu op € 1.20.
    Er wordt een spelletje gespeeld om wat aandelen goedkoop los te peuteren. Wie heeft een mening over een andere stategie.
    Eddy
  19. aossa 5 december 2008 16:45
    quote:

    eddy59 schreef:

    [quote=Nx4nX]
    Alle calls gaan scherp omlaag. En puts ook. Huh??
    [/quote]
    Inderdaad, echt vreemd mijn calls dec09 €12,00 stonden bij een koers van € 9,00 op € 2,00 en nu op € 1.20.
    Er wordt een spelletje gespeeld om wat aandelen goedkoop los te peuteren. Wie heeft een mening over een andere stategie.
    * rente gedaald (met 175 basispunten zelfs) => krijg je dus minder premie
    * aandeelkoers is langere tijd op nagenoeg zelfde koers blijven hangen, waardoor de impl.volatility afneemt
    * tijdwaarde die een beetje is afgenomen

    Nie neuten, wie in calls handelt moet de truuken van de foor kennen, anders afblijven !
278 Posts
Pagina: 1 2 3 4 5 6 ... 14 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 1,029 +0,10 +10,59%
JDE PEET'S 20,880 +0,64 +3,16%
PostNL 1,220 +0,03 +2,26%
Avantium 2,520 +0,05 +2,02%
AMG Critical Materials N.V. 14,320 +0,27 +1,92%
Sif Holding 12,220 +0,22 +1,83%
SBM Offshore 16,660 +0,26 +1,59%
TomTom 4,910 +0,08 +1,57%
Pharming 0,712 +0,01 +1,42%
EXOR NV 93,750 +1,30 +1,41%
NN Group 45,580 +0,58 +1,29%
ASR Nederland 44,450 +0,49 +1,11%
INPOST 15,460 +0,16 +1,05%
JUST EAT TAKEAWAY 12,775 +0,12 +0,95%
SIGNIFY NV 20,980 +0,18 +0,87%
ACOMO 17,780 +0,14 +0,79%
ASML 795,200 +5,70 +0,72%
Van Lanschot Kempen NV 39,000 +0,25 +0,65%
Aegon 5,636 +0,04 +0,64%
Fagron 19,080 +0,10 +0,53%
ADYEN NV 1.140,200 +5,80 +0,51%
Sligro 12,160 +0,06 +0,50%
WDP 24,700 +0,12 +0,49%
Heineken 79,800 +0,34 +0,43%
AMX 869,42 +3,64 +0,42%
Vopak 40,080 +0,16 +0,40%
Philips Koninklijke 25,920 +0,10 +0,39%
Fugro 22,100 +0,08 +0,36%
B&S Group SA 4,605 +0,02 +0,33%
ASCX 1.189,87 +3,87 +0,33%
UMG 22,180 +0,07 +0,32%
Basic-Fit 21,800 +0,06 +0,28%
IMCD 138,150 +0,35 +0,25%
NSI 20,250 +0,05 +0,25%
SHELL PLC 32,970 +0,07 +0,21%
Wolters Kluwer 151,000 +0,30 +0,20%
Corbion 20,920 +0,04 +0,19%
ING 15,358 +0,03 +0,18%
Wereldhave 13,980 +0,02 +0,14%
Ahold Delhaize 29,790 +0,03 +0,10%
ALLFUNDS GROUP 5,250 +0,00 +0,10%
ASMI 579,200 +0,20 +0,03%
AEX 889,16 +0,25 +0,03%
AZERION 1,498 0,00 0,00%
BESI 115,650 0,00 0,00%
Flow Traders 17,300 0,00 0,00%
HEIJMANS KON 25,450 0,00 0,00%
Kendrion 11,640 0,00 0,00%
RELX 41,260 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
ABN AMRO BANK N.V. 14,850 -0,52 -3,35%
Alfen N.V. 14,875 -0,36 -2,33%
PROSUS 32,440 -0,77 -2,32%
TKH 36,100 -0,52 -1,42%
Galapagos 22,040 -0,30 -1,34%
CM.COM 6,840 -0,09 -1,30%
NX FILTRATION 5,010 -0,06 -1,18%
ForFarmers 2,775 -0,03 -1,07%
OCI 26,250 -0,25 -0,94%
DSM FIRMENICH AG 116,500 -1,10 -0,94%
FASTNED 16,340 -0,14 -0,85%
RANDSTAD NV 41,310 -0,32 -0,77%
Nedap N.V. 56,400 -0,40 -0,70%
Eurocommercial Properties 23,150 -0,15 -0,64%
Vastned 23,550 -0,15 -0,63%
Akzo Nobel 53,080 -0,30 -0,56%
THEON INTERNAT 11,220 -0,06 -0,53%
RENEWI 7,780 -0,04 -0,51%
AALBERTS NV 33,300 -0,14 -0,42%
BAM 3,550 -0,01 -0,28%
CTP 16,180 -0,04 -0,25%
UNILEVER PLC 55,200 -0,10 -0,18%
Accsys 0,607 0,00 -0,16%
Aperam 24,940 -0,04 -0,16%
Air France-KLM 7,592 -0,01 -0,13%
KPN 3,586 0,00 -0,11%
Brunel 9,290 -0,01 -0,11%
Arcadis 62,800 -0,05 -0,08%
ArcelorMittal 19,755 -0,01 -0,05%
vlag naam koers verschil relatief verschil
AEX 889,24 +0,33 +0,04%
AEX GR 3.466,86 +3,07 +0,09%
Germany40^ 17.876,70 +64,65 +0,36%
FTSE 100 8.271,55 +36,32 +0,44%
EURO50 4.721,47 +15,33 +0,33%
US30^ 39.893,60 +138,00 +0,35%
Nasd100^ 19.001,10 +2,30 +0,01%
US500^ 5.444,56 +11,89 +0,22%
Japan225^ 36.048,60 -384,60 -1,06%
VD-NEW 16,94 -1,04 -5,77%
#/^ Index indications calculated real time, zie disclaimer